… opened doors to new treatment strategies that are not solely symptomatic. As opposed to
increasing dopamine and dopamine-associated signaling, current treatment strategies seek to …

… The efficacy of amantadine in the symptomatic treatment of patients with Parkinson's disease,
discovered serendipitously more than 50 years ago, has stood the test of time and the drug …

… risk of Parkinson’s disease (PD). The present study aimed to investigate the disease-modifying …
2A receptor antagonism, may require further investigation for designing new drugs. …

… as a new class of PD disease-modifying drugs. Future clinical trials, including those in
Table 2 , will provide more insight into the benefits of using different GLP-1R agonists for PD …

… In recent years, an emerging body of evidence has forged links between Parkinson’s
disease (PD) and type 2 diabetes mellitus (T2DM). In observational studies, those with T2DM …

… , the use of probiotics and prebiotics and faecal microbiota transplantation as potential
therapeutic approaches that may lead to a new treatment paradigm for Parkinson’s disease. …

Parkinson's disease (PD) is characterized by dopaminergic (DA) neuron loss and the formation
of cytoplasmic protein inclusions. Although the exact pathogenesis of PD is unknown, …

… Parkinson’s disease. The protective effect of autophagy on cell and animal PD models also
provides important evidence for autophagy as a new target for the PD treatment… new drugs for …

… Among several known targets, metformin can act as a complex I inhibitor (24), raising the
possibility that reducing mitochondrial respiration may constitute a surprising new treatment …

… as “tremor syndrome” in TCM, and Parkinson’s disease–like symptoms have been described
at length in ancient Chinese medicine books. PD was described as a disease with the …